Effect of soy phyto-eastrogens to people during menopause as soy have been shown to improve menopausal flusing symptoms. Nutritional, Metabolic, Endocrine Menopausal and female climacteric states
Conditions
Interventions
A bar containing 7.5g isolated soy protein powder (Solcon F) with 33mg of isoflavones (given twice daily) or 7.5g of the isolated soy (extracted, isoflavone free) protein alone (given twice daily) as
Sponsors
Hull and East Yorkshire Hospitals NHS Trust (UK)
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Women with a follicle-stimulating hormone (FSH) and luteinizing hormone (LH) greater than 20 mU/L and amenorrhoea for 1 year with or without vasomotor instability of hot flushing will be eligible to participate 2. Caucasian women
Exclusion criteria
Exclusion criteria: 1. Patients with liver dysfunction (ALT of greater than 135 u/L) or taking drugs that may interfere with liver function 2. Patients with impaired renal function (creatinine greater than 150, glomerular filtration rate less than 30) 3. Patients who have had antibiotic treatment within the last 6 months will also be ineligible for the study as antibiotics are known to change gut microflora and thus will interfere with phytoestrogen metabolism. This will also mean that patients who start taking antibiotics during the study will have to be withdrawn 4. Patients not wishing to allow disclosure to their GPs 5. Patients on any medication within 3 months of the study including steroid inhalers or HRT 6. Patients already self-supplementing with isoflavones 7. Vegetarian or vegans
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in bone turnover markers | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Insulin resistance 2. Blood pressure 3. Lipid profile 4. Endothelial function 5. Changes in endometrial thickness | — |
Countries
United Kingdom
Outcome results
None listed